Health Care Equipment

Resmed

ResMed and Oura Partner to Enhance Sleep Health Education and Care Pathways for US Members

Macquarie and Citibank Reiterate Buy Rating on ResMed CHESS Depositary Interests

Citigroup analyst maintains buy rating on ResMed

Morgan Stanley Analyst Maintains Buy Rating on ResMed CHESS Depositary Interests

Macquarie Reiterates Buy Rating on Resmed CHESS Depositary Interests

ResMed Submits Quarterly Report to SEC

Resmed released FY2026 Q3 earnings on May 1 After-Market EST, actual revenue USD 1.431 B (forecast USD 1.422 B), actual EPS USD 2.74 (forecast USD 2.7209)

Resmed released FY2026 9 Months earnings on May 1 After-Market EST, actual revenue USD 4.19 B, actual EPS USD 7.79

ResMed Stock Price Dropped Due to Downgrade by Wells Fargo

ResMed Reports Strong Q3 2026 Earnings

ResMed Reports Q3 Revenue Growth Below Estimates

Swiss Bank Analyst Maintains Buy Rating on ResMed's CHESS Depositary Interests

Resmed to Release FY2026 Q3 Earnings on April 30 After-Market EST, Forecast Revenue USD 1.423 B, EPS USD 2.7291

ResMed CEO Michael Farrell Sells Company Stock

Citigroup Analyst Maintains Buy Rating on ResMed

Citi Sees ResMed Q3 FY2026 Revenue at $1.44B but Margins Cut

ResMed Receives 'Moderate Buy' Consensus Recommendation from Fourteen Brokers

ResMed Inc. Honorary Chairman Peter C. Farrell Sells Company Common Stock

Andhra AP Fund Significantly Reduced Holdings in ResMed Inc.

ResMed Expands US Distribution Network with New Facility

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

ResMed Inc. (RMD) shares rose 1.12% to $204.15 on Monday, outperforming a mixed stock market session. The Dow Jones increased by 0.32%, while the S&P 500 fell by 0.07%. ResMed's stock remains 30.52% below its 52-week high of $293.81, reached on August 22nd. Trading volume was 1.0 million, below the 50-day average of 1.2 million.

MarketWatch Automated

iShares US Medical Devices

SPDR S&P Health Equip

iShares US Healthcare Providers

SPDR S&P Health

Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh

Dow Jones Industrial Average

S&P 500

Factset Research

ResMed Inc. Stock Rises Monday, Outperforms Market

Bank Julius Baer & Co. Ltd Zurich reduced its stake in ResMed Inc. by 17.9% in Q4, now holding 24,847 shares valued at $6,031,000. Other institutional investors also adjusted their positions. ResMed's stock opened at $202.55, with a market cap of $29.51 billion. The company reported a quarterly EPS of $2.86, exceeding estimates, and declared a dividend of $0.60 per share. Analysts have mixed ratings on the stock, with a consensus rating of 'Moderate Buy' and an average target price of $286.18.

Market Beat

HCA Healthcare

KeyCorp

Wells Fargo

JPMorgan Chase

Piper Sandler Cos

Citigroup

KEYCORP DEP SHS REP 1/40TH NON CUM PER PFD SER G

KEYCORP DEP SHS REPSTG 1/40TH INT PERP NON CUM H

KEYCORP DEP SHS REP 1/40TH PERP PFD SER F USD25

KEYCORP DEP SHS REP 1/40TH NON CUM PFD SER E

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A DD

WELLS FARGO & COMPANY 7.5% PERP CONV PRF CLS 'A' SERIES 'L'

WELLS FARGO & COMPANY DEP SHS REP 1/1000 INT PER PFD SER Y A

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A CC

WELLS FARGO & COMPANY 4.75% DEP SHS 1/1000 NCUM PFD CL A SR Z

WELLS FARGO & COMPANY DEP SHS REP 1/1000TH INT PFD SR AA (CLA)

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

CITIGROUP INC 6.250 NON CUM SER II PFD WI

Bank Julius Baer & Co. Ltd Zurich Lowers Stock Position in ResMed Inc. $RMD

Macquarie has reaffirmed its Buy rating on Resmed Inc CHESS Depositary Interests, maintaining a price target of A$46.50. Similarly, Citi also holds a Buy rating with a price target of A$48.00, as reported on May 7.

Tip Ranks

Macquarie Group Limited

Macquarie Group

Macquarie Keeps Their Buy Rating on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD)

Shares of ResMed Inc. (RMD) rose 2.53% to $203.79 on Tuesday, outperforming the mixed stock market where the Dow Jones increased by 0.11% and the S&P 500 decreased by 0.16%. This rise ended a three-day losing streak for ResMed, although the stock remains 30.64% below its 52-week high of $293.81 reached on August 22nd. Trading volume was 1.4 million, surpassing the 50-day average of 1.2 million.

ResMed Inc. Stock Rises Tuesday, Outperforms Market

Shares of ResMed Inc. (RMD) fell 3.87% to $198.76 on Monday, underperforming the market despite a favorable trading session for the S&P 500 and Dow Jones, both rising 0.19%. This marks the third consecutive day of losses for ResMed, which is currently 32.35% below its 52-week high of $293.81 reached on August 22nd. Trading volume was 1.8 million, surpassing the 50-day average of 1.2 million.

ResMed Inc. Stock Falls Monday, Underperforms Market

Citi analyst Laura Sutcliffe has maintained a Buy rating on Resmed Inc CHESS Depositary Interests, setting a price target of A$48.00. The shares closed at A$28.82. Sutcliffe, a 3-star analyst with a 53.69% success rate, focuses on the Healthcare sector. The consensus rating for Resmed is a Strong Buy, with an average price target of A$43.13.

Telix Pharmaceuticals Ltd.

Telix Pharmaceuticals

Sonic Healthcare Limited

Citi Keeps Their Buy Rating on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD)

Strs Ohio reduced its holdings in ResMed Inc. (NYSE:RMD) by 89.7% in Q4, owning 3,497 shares after selling 30,494 shares. Other hedge funds have also adjusted their positions, with Jones Financial increasing its stake by 52.6%. Insiders sold shares totaling $4.7 million in the last 90 days. Analysts have set new price targets, with Citigroup lowering its target to $340 and KeyCorp to $290. ResMed's stock opened at $206.83, with a market cap of $30.13 billion and a PE ratio of 19.94. The company reported earnings of $2.86 per share, exceeding estimates.

AllianceBernstein

Evercore

ResMed Inc. $RMD Shares Sold by Strs Ohio

Shares of ResMed Inc. (RMD) fell 1.31% to $206.89 on Thursday, underperforming the market as the S&P 500 Index dropped 0.38% and the Dow Jones Industrial Average fell 0.63%. The stock is currently 29.58% below its 52-week high of $293.81, reached on August 22nd. Trading volume was 1.3 million, surpassing the 50-day average of 1.1 million.

ResMed Inc. Stock Falls Thursday, Underperforms Market

Morgan Stanley analyst David Bailey has maintained a Buy rating on Resmed Inc CHESS Depositary Interests, with shares closing at A$28.78. The analyst consensus is Strong Buy, with a price target of A$43.13, indicating a potential upside of 49.86%. Bailey, a 4-star analyst, also previously set a price target of A$41.72 in a May report. He covers the Healthcare sector, focusing on companies like Ramsay Health Care and Telix Pharmaceuticals.

Morgan Stanley

Ramsay Health Care Limited

Cochlear Limited

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD) Receives a Buy from Morgan Stanley

Resmed(RMD.US)